TONIX PHARMACEUTICALS HOLDING CORP.: investing cash flow
Investing cash flow for TONIX PHARMACEUTICALS HOLDING CORP. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All TONIX PHARMACEUTICALS HOLDING CORP. financial histories
What this measure means
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
Exact concept: us-gaap:NetCashProvidedByUsedInInvestingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -4,528,000 | USD | 2026-03-12 | 10-K · 0001999371-26-005730 |
| 2024-01-01 | 2024-12-31 | -120,000 | USD | 2026-03-12 | 10-K · 0001999371-26-005730 |
| 2023-01-01 | 2023-12-31 | -29,070,000 | USD | 2025-03-18 | 10-K · 0001999371-25-002786 |
| 2022-01-01 | 2022-12-31 | -48,147,000 | USD | 2024-04-01 | 10-K · 0001999371-24-004297 |
| 2021-01-01 | 2021-12-31 | -35,307,000 | USD | 2023-03-13 | 10-K · 0001387131-23-003377 |
| 2020-01-01 | 2020-12-31 | -8,564,000 | USD | 2022-03-14 | 10-K · 0001387131-22-003640 |
| 2019-01-01 | 2019-12-31 | -17,000 | USD | 2021-03-15 | 10-K · 0001387131-21-003550 |
| 2018-01-01 | 2018-12-31 | -6,000 | USD | 2020-03-24 | 10-K · 0001387131-20-003189 |
| 2017-01-01 | 2017-12-31 | 7,169,000 | USD | 2019-03-18 | 10-K · 0001387131-19-002012 |
| 2016-01-01 | 2016-12-31 | 16,549,000 | USD | 2018-03-09 | 10-K · 0001615774-18-001762 |
| 2012-01-01 | 2012-12-31 | -35,763 | USD | 2013-11-22 | 10-K/A · 0001144204-13-063785 |
| 2011-01-01 | 2011-12-31 | 302 | USD | 2013-11-22 | 10-K/A · 0001144204-13-063785 |
| 2010-01-01 | 2010-12-31 | -94,366 | USD | 2012-03-30 | 10-K · 0001144204-12-019081 |
Related financial histories
- TONIX PHARMACEUTICALS HOLDING CORP.: total assets
- TONIX PHARMACEUTICALS HOLDING CORP.: total liabilities
- TONIX PHARMACEUTICALS HOLDING CORP.: stockholders equity
- TONIX PHARMACEUTICALS HOLDING CORP.: cash and cash equivalents
- TONIX PHARMACEUTICALS HOLDING CORP.: net income or loss
- TONIX PHARMACEUTICALS HOLDING CORP.: operating cash flow
- TONIX PHARMACEUTICALS HOLDING CORP.: capital expenditure payments
- TONIX PHARMACEUTICALS HOLDING CORP.: contract revenue excluding tax
- TONIX PHARMACEUTICALS HOLDING CORP.: financing cash flow
- TONIX PHARMACEUTICALS HOLDING CORP.: retained earnings or deficit
- TONIX PHARMACEUTICALS HOLDING CORP.: basic weighted-average shares
- TONIX PHARMACEUTICALS HOLDING CORP.: diluted weighted-average shares
- TONIX PHARMACEUTICALS HOLDING CORP.: basic earnings per share
- TONIX PHARMACEUTICALS HOLDING CORP.: diluted earnings per share
- TONIX PHARMACEUTICALS HOLDING CORP.: net property, plant and equipment
- TONIX PHARMACEUTICALS HOLDING CORP.: share-based compensation expense
- TONIX PHARMACEUTICALS HOLDING CORP.: operating income or loss
- TONIX PHARMACEUTICALS HOLDING CORP.: current assets
- TONIX PHARMACEUTICALS HOLDING CORP.: current liabilities
- TONIX PHARMACEUTICALS HOLDING CORP.: current accounts payable
- TONIX PHARMACEUTICALS HOLDING CORP.: operating expenses
- TONIX PHARMACEUTICALS HOLDING CORP.: cost of revenue
- TONIX PHARMACEUTICALS HOLDING CORP.: selling, general and administrative expense
- TONIX PHARMACEUTICALS HOLDING CORP.: research and development expense
Inspect the source
- Entity
- TONIX PHARMACEUTICALS HOLDING CORP. / CIK 0001430306
- Captured
- 2026-09-20T09:02:25.703Z
- SEC response SHA-256
c58b9668b329c3fe1faf138366f8781d658cf50824bc6e133ce4aa43029ca9ed
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001430306.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))